Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Change in Acquisitions & Divestments (2021 - 2026)

Oric Pharmaceuticals filings provide 6 years of Change in Acquisitions & Divestments readings, the most recent being $60.0 million for Q1 2026.

  • Quarterly Change in Acquisitions & Divestments fell 31.43% to $60.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $225.0 million through Mar 2026, down 27.42% year-over-year, with the annual reading at $252.5 million for FY2025, 8.26% down from the prior year.
  • Change in Acquisitions & Divestments hit $60.0 million in Q1 2026 for Oric Pharmaceuticals, down from $62.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $87.5 million in Q1 2025 and bottomed at $10.0 million in Q1 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $57.2 million, with a median of $58.2 million recorded in 2023.
  • The largest annual shift saw Change in Acquisitions & Divestments tumbled 84.85% in 2022 before it skyrocketed 464.75% in 2023.
  • Oric Pharmaceuticals' Change in Acquisitions & Divestments stood at $60.2 million in 2022, then dropped by 16.99% to $50.0 million in 2023, then surged by 55.03% to $77.5 million in 2024, then decreased by 19.35% to $62.5 million in 2025, then dropped by 4.0% to $60.0 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Change in Acquisitions & Divestments are $60.0 million (Q1 2026), $62.5 million (Q4 2025), and $55.0 million (Q3 2025).